FDA & Government News

Wegovy HD Secures FDA Approval

Semaglutide 7.2 mg achieved 20.7% mean weight loss in STEP UP trials.

Share

  • 1

    Semaglutide 7.2 mg (Wegovy HD) approved by FDA.

  • 2

    Effective in reducing weight in adults with obesity and type 2 diabetes.

  • 3

    Mean weight loss: 20.7% in obesity trial, 14.1% in diabetes trial.

  • 4

    Safety profile consistent with previous studies.

  • 5

    Additional approvals include reducing major cardiovascular event risks.

  • 6

    Launch in single-dose pen expected in April

  • 7

    Previously approved in lower doses for weight management.

Original Source(s)

Wegovy HD Secures FDA Approval

  • by Kathryn Wighton

  • March 19, 2026

Related Content

Wearable Trackers: These Activity Metrics Drive Calorie Burn

Machine learning model shows intensity and distance—not light activity—shape energy expenditure.

Expanding CGM Access for Medicare Patients

“Insurance coverage of CGM is frequently identified in the literature as a barrier to CGM access."

Evaluating AI for thyroid nodule diagnosis

Ultrasound based AI–assisted diagnostic systems “demonstrated high clinical potential."